Intellia Therapeutics, Inc.NTLA

Intellia Therapeutics Inc. is still a pre-commercial biotech with $134.7 million in cash and equivalents at 31 March 2026, but its income statement tells a different story: revenue of $15.0 million, a net loss of $96.2 million, and an operating loss of $100.5 million for the quarter. The company’s single revenue line continues to be $5.1-$5.2 million per quarter from its 2016 Regeneron collaboration, not from any in-house product. (source: NTLA 10-Q (2026-05-11), https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm)

The company pitches itself as a CRISPR powerhouse, complete with a press kit of headshots and logos, but its filings are the real document of record. For the three months to 31 March 2026, Intellia spent $80.7 million on research and development while generating only $15.0 million of top-line revenue, leaving it with a net loss of $96.2 million and negative operating cash flow of $117.3 million. The 10-Q shows property, plant and equipment spending of just $79,000, underscoring that the business is still a research engine, not a commercial one. (source: NTLA 10-Q (2026-05-11), https://www.sec.gov/Archives/edgar/data/1652130/000119312526215740/ntla-20260331.htm)

Intellia’s lead programme, lonvoguran ziclumeran (lonvo-z), is the focus of a 13 June 2026 press release boasting “additional positive Phase 3 results” in hereditary angioedema, but the release lives in the press room while the 10-Q shows zero product revenue. The company’s collaboration income with Regeneron remains the only visible cash in the financial statements, at $5.2 million in Q1 2026 versus $5.1 million in Q1 2025. (source: NTLA press release (2026-06-13), https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-ex99_1.htm)

The company’s public filings show a steady stream of insider selling via Rule 144 blocks, including a $6.8 million tranche filed on 2 July 2026, while the board has not authorised any buybacks. Dilution risk remains live: the diluted share count stood at 118.5 million for the quarter, leaving ample headroom for further issuance. (source: NTLA 144 (2026-07-02), https://www.sec.gov/Archives/edgar/data/1652130/000195004726006836/xsl144X01/primary_doc.xml)

Despite the CRISPR gloss in the press kit, the numbers tell a simpler story: Intellia is a cash-burning research vehicle with a single collaboration revenue stream, no commercial product, and a burn rate that outpaces its cash generation. The 8-K filed on 15 June 2026 confirms the company’s focus on pipeline execution rather than near-term monetisation, underscoring the gap between narrative and accounts. (source: NTLA 8-K (2026-06-15), https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm)

The company’s SEC filings remain the only reliable window into its progress. The latest 10-Q, the June press release, and the recent 144 filings all point in one direction: product revenue is still aspirational, dilution risk is real, and the timeline to profitability remains unproven. Until a commercial product ships and generates recurring revenue, the story is less about CRISPR headlines and more about cash arithmetic. (source: NTLA SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1652130)